Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
BROCADE3 demonstrated a progression-free survival benefit favouring the veliparib arm, with median progression-free survival 14.5 vs 12.6 months (HR 0.71; 95% CI 0.57-0.88, P=0.002).
“The study demonstrated a PFS benefit favouring the veliparib arm, with a median PFS of 14.5 versus 12.6 months (HR 0.71; 95% CI 0.57-0.88, P = 0.002)”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [79]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cited by
Sorted by citations
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M. S., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G. S., Biganzoli, L., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.09.010 · Cited by 1,369 · see citing works
Self-citation
- Authors
- Diéras, V. C., Han, H. S., Kaufman, B., Wildiers, H., Friedlander, M., Ayoub, J.-P., Puhalla, S. L., Bondarenko, I., Campone, M., Jakobsen, E. H., Jalving, M., Oprean, C., Palácová, M., Park, Y. H., Shparyk, Y., Yañez, E., Dudley, M., Ratajczak, C. K., Maag, D., & Arun, B. K.
- Affiliations
- Moffitt Cancer Center (US)
- Sheba Medical Center (IL)
- Universitair Ziekenhuis Leuven (BE)
- UNSW Sydney (AU)
- Centre Hospitalier de l’Université de Montréal (CA)
- UPMC Health System (US)
- Dnipro State Medical University (UA)
- Institut de Cancérologie de l'Ouest (FR)
- Vejle Sygehus (DK)
- University Medical Center Groningen (NL)
- Victor Babeș University of Medicine and Pharmacy Timișoara (RO)
- Masaryk Memorial Cancer Institute (CZ)
- Samsung Medical Center (KR)
- AbbVie (United States) (US)
- The University of Texas MD Anderson Cancer Center (US)
- ORCID
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2019-10
- Volume
- 30
- Pages
- v857-v858
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2978854127
- Cited by
- 32
- References
- 0
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2022: 1 · 2021: 11 · 2020: 15 · 2019: 1
- FWCI
- 3.03
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Annals of Oncology (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
- Funders
- U.S. Department of Defense
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Teva Pharmaceutical Industries
- Celgene
- F. Hoffmann-La Roche
- Novartis Pharmaceuticals Corporation
- Celltrion Healthcare
- Celldex Therapeutics
- Les Laboratories Pierre Fabre
- BeiGene
- Incyte
- Celltrion
- Puma Biotechnology
- Eisai
- Astellas Pharma
- Vifor Pharma
- Servier
- PharmaMar
- Genentech
- Daiichi Sankyo Europe
- Cilag
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Advanced Breast Cancer Therapies
- Keywords
- veliparib, PARP inhibitors, BRCA1 mutation, BRCA2 mutation, HER2-negative breast cancer, metastatic breast cancer, carboplatin, paclitaxel, homologous recombination deficiency, platinum resistance, progression-free survival, overall survival, neutropenia, thrombocytopenia, anemia, dose reduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
